NCT05358535 Propofol and Etomidate Admixtures Comparisons Trial (PEAC Trial)
| NCT ID | NCT05358535 |
| Status | Recruiting |
| Phase | Phase 3 |
| Sponsor | University of Texas Southwestern Medical Center |
| Condition | Anesthesia |
| Study Type | INTERVENTIONAL |
| Enrollment | 200 participants |
| Start Date | 2022-09-19 |
| Primary Completion | 2027-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 3 trials are large pivotal studies comparing the treatment to current standard of care or placebo. Your participation directly contributes to the evidence needed for regulatory approval.
This trial targets 200 participants in total. It began in 2022-09-19 with a primary completion date of 2027-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to evaluate the hemodynamics and adverse event profile in comparison between two treatment arms, one using an admixture of propofol and etomidate at a ratio by volume of 25%/75% (P2E7), and one using an admixture of propofol and etomidate at a ratio by volume of 75%/25% (P7E2), for anesthesia during endoscopic procedures at the Clements University Hospital (CUH) endoscopy lab (Endo).
Eligibility Criteria
Inclusion Criteria: 1. Adult patients (age ≥18 years old) 2. Having endoscopic procedure at CUH with anesthesia 3. ASA 3 or above 4. Ejection Fraction test result available Exclusion Criteria: 1. Known allergies or adverse reactions to study drugs or study drug components or preservatives 2. Patient refusal 3. Clinician refusal 4. Documented cognitive impairments precluding subject ability to consent for themselves unless a surrogate documented legally acceptable decision maker consents for patient participation 5. Prisoner or incarcerated or patients held by law enforcement officials in custody 6. Pregnancy or patient refusal for pregnancy testing or screening (standard UTSW policy and protocol requires pregnancy testing for appropriate patients prior to anesthesia)
Contact & Investigator
Kapil Anand
STUDY DIRECTOR
University of Texas
Frequently Asked Questions
Who can join the NCT05358535 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Anesthesia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT05358535 trial and what does that mean for participants?
Phase 3 trials are large-scale studies comparing the new treatment to existing standards of care or a placebo. They provide the evidence needed for regulatory approval. This trial targets 200 participants.
Is NCT05358535 currently recruiting?
Yes, NCT05358535 is actively recruiting participants. Contact the research team at christopher.choi@utsouthwestern.edu for enrollment information.
Where is the NCT05358535 trial being conducted?
This trial is being conducted at Dallas, United States.
Who is sponsoring the NCT05358535 clinical trial?
NCT05358535 is sponsored by University of Texas Southwestern Medical Center. The principal investigator is Kapil Anand at University of Texas. The trial plans to enroll 200 participants.